Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-anthracycline Chemo for Elderly HER2+ Breast Cancer
NCT02102438Withdrawn
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab, paclitaxel and carboplatin in HER2-positive breast cancer, sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: Disease Free Survival at 3 years. Planned start Apr 2014; status: withdrawn.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02102438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02102438.